[Skip to Content]
[Skip to Content Landing]
JAMA Insights
Clinical Update
April 30, 2019

Active Surveillance of Low-Risk Thyroid Cancer

Author Affiliations
  • 1Section of Endocrine Surgery, Department of Surgery, University of California, Los Angeles David Geffen School of Medicine, Los Angeles
  • 2Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of California, Los Angeles
  • 3Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles
JAMA. 2019;321(20):2020-2021. doi:10.1001/jama.2019.5350

In the past year, there were an estimated 53 990 new cases of thyroid cancer in the United States, representing a 3-fold increase in incidence during the past 3 decades.1 While most of this increase has been attributed to sonographic detection of small, localized papillary thyroid cancers, there has been an increase in incidence of all stages of thyroid cancer.2,3 Despite this increase in the number of individuals diagnosed with thyroid cancer, mortality has increased only slightly and has ranged from 0.4 to 0.5 per 100 000 people per year since 1980. Approximately 2060 people were estimated to die from thyroid cancer in the United States in 2018.1

×